Plant cell bioreactors
Controlled cultivation of selected plant cells for consistent, scalable research and development.
Plant cell–based biotechnology
Plant cell–based production of novel therapeutics
Leysin Therapeutics is developing a platform that combines controlled plant-cell cultivation, bioprocessing, precision formulation and targeted delivery to explore new therapeutic possibilities.
A symphony of receptor activation, paired with targeted neurotransmitter release.
Novel molecule programmes
Development-stage work spanning cannabinoid, tryptamine and aminoindane-related programmes.
Precision formulation
Formulation approaches intended to improve stability, handling and delivery precision.
Targeted delivery
Delivery research designed around receptor engagement and the biology of brain signalling.
Our platform
From plant cells to precision therapeutics.
The platform is being developed around the biosynthetic potential of plant and other biological source systems, coupled with bioprocessing, analytical chemistry and formulation science.
The aim is to create a controlled development path from source material to characterised compounds and ultimately to research-ready formulations.
Explore our platform →Conceptual development pathway
Source & geneticsSelected biological starting material
Cell cultureControlled bioreactor cultivation
CharacterisationIsolation, analysis and formulation
Delivery researchTargeted therapeutic development
Illustrative pathway. Specific programmes remain development-stage and subject to scientific and regulatory review.
Balance
The formulation thesis
From single notes to a coordinated biological response.
Leysin’s working concept is to move beyond isolated receptor targets and investigate carefully designed combinations intended to create a broader, coordinated pattern of receptor activity and neurotransmitter signalling.
This “chemical symphony” framing guides how the team thinks about balance, formulation and the interaction between exogenous compounds and endogenous biology.
Read about delivery & formulation →Development programmes
A focused set of research directions.
The categories below reflect current development themes shared by the team; they do not represent approved products or clinical claims.
Cannabinoid genetics
Plant-cell production research built around selected cannabis genetics and reproducible biosynthetic output.
5-MeO-DMT pathways
Research into tryptamine biosynthesis, characterisation and formulation, informed by prior work in 5-MeO-DMT analytics.
Aminoindane precursors
Exploratory work around precursor systems and their potential role in future multi-component formulations.
Special projects
Selected discovery programmes kept intentionally undisclosed while feasibility, partnerships and IP are evaluated.
Our people
A multidisciplinary team with a shared vision.
David Henry
International Business Leader
Operations, organisational development and strategic growth across Europe, the UK and Southern Africa.
Alison Henry, MA, BSc
Director of Clinical Research
Clinical research, counselling psychology, contemplative practice and translational thinking.
Philippe Henry, PhD
Director of Preclinical Research
Molecular genetics, bioinformatics, cannabis genomics and biotechnology research leadership.